Neuraxis, Inc. NRXS
7.56
(0.19)
(2.45%)
as of 25 Sep
- Market cap
- $97.3M
- P/E
- 0.0×
Follow NRXS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(3,433.40%) | (315.62%) | (269.21%) | (153.96%) | |
| (240.65%) | (154.37%) | (137.13%) | (98.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(432.27%) | (285.58%) | (149.62%) | (132.43%) | |
Average Days of Receivables |
11.78 | 20.01 | 32.82 | 29.72 | |
Free Cash Flow per Share |
(0.64) | (0.73) | (0.55) | (0.47) | |
Free Cash Flow |
(6.28) | (6.60) | (6.06) | (5.64) | |
Capital Expenditures |
(0.03) | (0.17) | — | (0.02) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(93.92%) | (76.91%) | (47.24%) | (37.33%) | |
Accounts Receivable Turnover |
41.74 | 16.21 | 13.62 | 18.94 | |
Accounts Payable Turnover |
0.58 | 1.53 | 1.53 | 1.22 | |
Inventory Turnover |
8.10 | 3.74 | 4.66 | 3.76 | |
Average Days of Payables |
601.37 | 90.39 | 173.63 | 376.31 | |
Days of Inventory on Hand |
74.83 | 166.71 | 135.52 | 131.82 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
18.19% | 13.83% | 11.10% | 11.94% | |
Selling, General and Administrative Expense of Revenue |
291.24% | 289.77% | 243.84% | 218.14% | |
Share Based Compensation of Revenue |
13.08% | 16.72% | 19.16% | 24.21% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.75 | 0.75 | 0.67 | |
Depreciation/Fixed assets |
0.49 | 0.79 | 1.03 | 1.12 | |
Capex/Depreciation |
(0.60) | (2.89) | 0.00 | (0.27) | |
Revenue per Share |
0.34 | 0.39 | 0.39 | 0.44 | |
Operating CF per Share |
(0.63) | (0.71) | (0.55) | (0.46) | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.05 | 0.00 | 0.00 | |
Net Profit Margin |
(247.62%) | (241.37%) | (188.57%) | (159.01%) |
Columns are period end dates